GSK8573

CAS No. 1693766-04-9

GSK8573( —— )

Catalog No. M22027 CAS No. 1693766-04-9

GSK8573 is an inactive control compound for GSK2801. GSK8573 has binding activity to BRD9 (Kd of 1.04 μM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 29 In Stock
5MG 30 In Stock
10MG 48 In Stock
25MG 91 In Stock
50MG 142 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    GSK8573
  • Note
    Research use only, not for human use.
  • Brief Description
    GSK8573 is an inactive control compound for GSK2801. GSK8573 has binding activity to BRD9 (Kd of 1.04 μM).
  • Description
    GSK8573 is an inactive control compound for GSK2801. GSK8573 has binding activity to BRD9 (Kd of 1.04 μM).
  • In Vitro
    GSK8573 (1.0 μM) has binding activity to BRD9 with a Kd value of 1.04 μM and is inactive against BAZ2A/B and other bromodomain family.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    Epigenetic Reader Domain
  • Recptor
    BRD9
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1693766-04-9
  • Formula Weight
    323.39
  • Molecular Formula
    C20H21NO3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:22 mg/mL (68.03 mM; Need ultrasonic)
  • SMILES
    CCCOC1=CC2=C(C=C(N2C=C1)C(C)=O)C1=CC(OC)=CC=C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Chen P, et al. Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B. J Med Chem. 2016 Feb 25;59(4):1410-24.
molnova catalog
related products
  • BRD4-IN-4

    BRD4-IN-4 is a selective BRD4 inhibitor with an IC50 value of 6.83 μM for BRD4.BRD4-IN-4 selectively inhibits the proliferation of the MV4-11 cell line and arrests the cells in G1 phase.BRD4-IN-4 can be used to study MLL leukemias.

  • Curcumin

    Curcumin is a natural phenolic compound with impressive antioxidant properties. Curcumin is recently proved to exert its chemopreventive effects partly through the activation of nuclear factor (erythroid-2 related) factor 2 (Nrf2).

  • Y06137

    Y06137 is an effective and selective BET inhibitor with a Kd of 81 nM for BRD4(1) bromodomain. Y06137 can be used for research on the treatment of castration-resistant prostate cancer.